Athira Pharma, makers of experimental Alzheimer’s drug fosgonimeton, paid up $4 million to settle a federal case following allegations that the company manipulated scientific…
A recent Science investigation found that Eliezer Masliah, one of the world’s leading Alzheimer’s and Parkinson’s researchers, engaged in research misconduct over the course…
Precision medicine is a medical approach that considers a patient’s genes, environment, and lifestyle. In the realm of Alzheimer’s disease, experts are pushing for…
For decades, scientists blamed Alzheimer’s disease on the buildup of beta-amyloid protein plaques in the brain. But most clinical trials for drugs intended to…
On November 25th, Cassava Sciences announced their experimental Alzheimer’s drug simufilam failed to slow cognitive or functional decline in its 52-week Phase 3 trial….
At the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, scientists and drug development companies gathered to report on recent successes…
For years, a commonly prescribed treatment for managing the symptoms of Alzheimer’s disease has been a type of drug called a cholinesterase inhibitor (ChEI)….
Parasites take an enormous toll on human and veterinary health. But researchers may have found a way for patients with brain disorders and a…
The new monoclonal anti-amyloid Alzheimer’s drugs are a constant source of controversy among doctors, insurers, and regulators worldwide. One of this buzzy new drug class,…
Athira Pharma’s experimental Alzheimer’s drug fosgonimeton hit a speedbump on its way toward FDA approval: The treatment failed to show a clinical benefit in…
In February, Biogen announced it was pulling Aduhelm off the market. The company will continue supplying the drug until November but stopped providing it…
Members of the Being Patient community are increasingly curious to learn their genetic status as it relates to Alzheimer’s risk. A story I was…
During the Alzheimer’s Association International Conference in Philadelphia last week, researchers and drug companies presented data on a range of different Alzheimer’s drugs. Amidst…
On July 25th, European regulators said no to Eisai and Biogen’s anti-amyloid drug Leqembi for early stage Alzheimer’s. The European Medicines Agency (Europe’s version…
Cassava Sciences’ experimental Alzheimer’s drug simufilam is currently in clinical trials. Meanwhile, the company is experiencing a major shake-up. Its CEO and lead neuroscientist…